|
アサノ スミエ
Sumie Asano
浅野 澄恵 所属 川崎医科大学 医学部 臨床医学 リウマチ・膠原病学 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Risk Factors for Chronic Damage Accumulation Across Different Onset Eras in Systemic Lupus Erythematosus: A Cross-sectional Analysis of a Lupus Registry of Nationwide Institutions (LUNA). |
| 掲載誌名 | 正式名：Acta medica Okayama 略 称：Acta Med Okayama ISSNコード：0386300X/0386300X |
| 掲載区分 | 国内 |
| 巻・号・頁 | 74(3),pp.191-198 |
| 著者・共著者 | Ohashi Keiji, Sada Ken-Ei, Asano Yosuke, Hayashi Keigo, Yamamura Yuriko, Asano Sumie Hiramatsu, Miyawaki Yoshia, Morishita Michiko, Katsuyama Eri, Watanabe Haruki, Tatebe Noriko, Narazaki Mariko, Matsumoto Yoshinori, Sunahori-Watanabe Katsue, Kawabata Tomoko, Yajima Nobuyuki, Wada Jun |
| 発行年月 | 2020/06 |
| 概要 | Chronic damage accumulation affects not only mortality but also quality of life in patients with systemic lupus erythematosus (SLE). Risk factors for chronic damage were explored in SLE through different onset eras. Two hundred forty-five patients at Okayama University Hospital and Showa University Hospital were divided into three groups based on the onset era: a past-onset group (onset before 1995; n=83), middle-onset group (1996-2009; n=88), and recent-onset group (after 2010; n=74). The mean Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score as an index of chronic damage was 1.93, 1.24, and 0.53 in the past-, middle-, and recent-onset groups, respectively. In the pastonset group, the total SDI score was significantly associated with glucocorticoid monotherapy by linear regression analysis (β-coefficient [β]=0.63; 95% confidence interval [CI], 0.21-1.05) and C-reactive protein levels (β=0.67; 95% CI, 0.27-1.07). In the middle-onset group, the total SDI score was significantly associated with the SLE Disease Activity Index at registration (β=0.09; 95% CI, 0.03-0.12). Reducing the accumulation of chronic damage in SLE patients might be possible with the concomitant use of immunosuppressants and tight control of disease activity. |
| DOI | 10.18926/AMO/59949 |
| PMID | 32577016 |